Insider · CIK 0001947731
Doug Besch
Files at OPRX (OptimizeRx Corp). First filing -, latest -.
In brief
Doug Besch files SEC Form 4 as officer at OPRX (OptimizeRx Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Doug Besch has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | OPRX OptimizeRx Corp | FTax withholding Common Stock | -4,079 | $12.74 | $52k | 66,876 | Dec 23, 2025 |
| Dec 19, 2025 | OPRX OptimizeRx Corp | MOption exercise Common Stock | +1,964 | $0.00 | $0 | 71,536 | Dec 22, 2025 |
| Dec 19, 2025 | OPRX OptimizeRx Corp | FTax withholding Common Stock | -581 | $13.51 | $7,849 | 70,955 | Dec 22, 2025 |
| Dec 19, 2025 | OPRX OptimizeRx Corp | MOption exercise Restricted Stock Unitsderivative | -1,964 | $0.00 | $0 | 1,964 | Dec 22, 2025 |
| Oct 3, 2025 | OPRX OptimizeRx Corp | MOption exercise Common Stock | +3,325 | $0.00 | $0 | 70,555 | Oct 7, 2025 |
| Oct 3, 2025 | OPRX OptimizeRx Corp | FTax withholding Common Stock | -983 | $18.75 | $18k | 69,572 | Oct 7, 2025 |
| Oct 3, 2025 | OPRX OptimizeRx Corp | MOption exercise Restricted Stock Unitsderivative | -3,325 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Aug 21, 2025 | OPRX OptimizeRx Corp | AGrant or award Common Stock | +15,625 | $0.00 | $0 | 67,230 | Aug 25, 2025 |
| Aug 21, 2025 | OPRX OptimizeRx Corp | AGrant or award Stock Optionderivative | +35,156 | $0.00 | $0 | 35,156 | Aug 25, 2025 |
| Feb 15, 2025 | OPRX OptimizeRx Corp | FTax withholding Common Stock | -1,386 | $6.64 | $9,203 | 51,605 | Feb 20, 2025 |
| Dec 23, 2024 | OPRX OptimizeRx Corp | AGrant or award Common Stock | +41,408 | $0.00 | $0 | 52,991 | Dec 27, 2024 |
| Dec 23, 2024 | OPRX OptimizeRx Corp | AGrant or award Stock Optionderivative | +77,742 | $0.00 | $0 | 77,742 | Dec 27, 2024 |
| Dec 19, 2024 | OPRX OptimizeRx Corp | MOption exercise Common Stock | +1,964 | $0.00 | $0 | 12,160 | Dec 20, 2024 |
| Dec 19, 2024 | OPRX OptimizeRx Corp | FTax withholding Common Stock | -577 | $4.75 | $2,741 | 11,583 | Dec 20, 2024 |
| Dec 19, 2024 | OPRX OptimizeRx Corp | MOption exercise Restricted Stock Unitsderivative | -1,964 | $0.00 | $0 | 3,928 | Dec 20, 2024 |
| Feb 15, 2024 | OPRX OptimizeRx Corp | AGrant or award Common Stock | +4,000 | $0.00 | $0 | 7,848 | Apr 24, 2024 |
| Dec 19, 2023 | OPRX OptimizeRx Corp | AGrant or award Stock Optionderivative | +5,892 | $0.00 | $0 | 5,892 | Feb 21, 2024 |
| Dec 19, 2023 | OPRX OptimizeRx Corp | AGrant or award Restricted Stock Unitsderivative | +5,892 | $0.00 | $0 | 5,892 | Feb 21, 2024 |
Questions about Doug Besch
Answered from the filings on this page, as of the latest one.
Is Doug Besch buying or selling?
Doug Besch has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Doug Besch's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Doug Besch has 0.
Where does Doug Besch file Form 4?
Doug Besch has filed Form 4 at OPRX (OptimizeRx Corp) as Chief Product Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.